Abstract
Fifty-five patients placed on tipranavir/ritonavir 500/200 mg twice a day (27 with enfuvirtide and 28 without) underwent tipranavir and ritonavir plasma concentration measurements by high-pressure liquid chromatography. Markedly higher tipranavir and ritonavir trough concentrations were observed in enfuvirtide recipients. The modelling of sparse plasma samples using a first order absorption and elimination monocompartmental model without time lag predicted higher tipranavir elimination half-life and volume of distribution in enfuvirtide takers. This unexpected drug-drug interaction warrants further investigation.
MeSH terms
-
Anti-HIV Agents / pharmacokinetics*
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Cohort Studies
-
Drug Interactions
-
Enfuvirtide
-
Female
-
HIV Envelope Protein gp41 / therapeutic use
-
HIV Fusion Inhibitors / pharmacokinetics
-
HIV Fusion Inhibitors / therapeutic use
-
HIV Infections / drug therapy
-
HIV Protease Inhibitors / pharmacokinetics
-
HIV Protease Inhibitors / therapeutic use
-
HIV-1
-
Half-Life
-
Humans
-
Male
-
Peptide Fragments / pharmacokinetics*
-
Peptide Fragments / therapeutic use
-
Pyridines / pharmacokinetics*
-
Pyridines / therapeutic use
-
Pyrones / pharmacokinetics*
-
Pyrones / therapeutic use
-
Ritonavir / pharmacokinetics*
-
Ritonavir / therapeutic use
-
Sulfonamides
Substances
-
Anti-HIV Agents
-
HIV Envelope Protein gp41
-
HIV Fusion Inhibitors
-
HIV Protease Inhibitors
-
Peptide Fragments
-
Pyridines
-
Pyrones
-
Sulfonamides
-
Enfuvirtide
-
Ritonavir
-
tipranavir